Press Releases

Altasciences has been recognized in contract research with a 2024 CRO Leadership Award for Capabilities, marking the ninth year that the company has been deemed a top performer. Read more!

The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.

Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO. The impressive 8,000-square-foot space features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.

Virpax Pharmaceuticals Inc. has chosen Altasciences to conduct preclinical studies in support of their new drug, an intranasal spray, GCPQ, under the trade name, AnQlar. Click to read more.

Altasciences is pleased to have completed the successful Phase I trial of Ischemix’ novel drug candidate, CMX-2043, for the treatment of acute traumatic brain injury (TBI), at our Montréal clinical facility.

Altasciences has been recognized for excellence in contract research with a 2023 CRO Leadership Award for Capabilities. This marks the eighth year that Altasciences, a fully integrated drug development solution company, has been deemed a top performer.